Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Svitlana Tatulych
Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study
Journal of the American Academy of Dermatology
Dermatology
Related publications
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study
Arthritis Research & Therapy
SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study
Clinical Efficacy or Tildrakizumab in Patients With Chronic Plaque Psoriasis Over 2 Years of Treatment: Results From Long-Term Extensions to 2 Phase 3 Clinical Studies
SKIN The Journal of Cutaneous Medicine
Long-Term Metformin Treatment in Adolescents With Obesity and Insulin Resistance, Results of an Open Label Extension Study
Nutrition and Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Efficacy of Lanadelumab in Hereditary Angioedema Patients Switching From C1 Inhibitor Long-Term Prophylaxis: Interim Results From the HELP Open-Label Extension Study
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Long-Term Safety and Efficacy of Etanercept in Children and Adolescents With Plaque Psoriasis
Journal of the American Academy of Dermatology
Dermatology
Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial
SKIN The Journal of Cutaneous Medicine
